Patents by Inventor Patrizia TISSELLI

Patrizia TISSELLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20170334915
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Inventors: George HYND, Patrizia TISSELLI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, John Gray MONTANA, Stephen Colin PRICE
  • NEW COMPOUNDS AS NIK INHIBITORS
    Publication number: 20170334906
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Inventors: George HYND, Patrizia TISSELLI, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Sameul Edward MANN, Stephen Colin PRICE, John Gray MONTANA
  • NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20170334900
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Inventors: George HYND, Patrizia TISSELLI, Janusz Josef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, John Gary MONTANA, Stephen Colin PRICE, Fabien Jean Ghislain ROUSSEL
  • 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer
    Patent number: 9643964
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 9, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: George Hynd, Stephen Price, Janusz Kulagowski, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, Patrizia Tisselli, John Gary Montana
  • NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20160257679
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: September 25, 2014
    Publication date: September 8, 2016
    Inventors: George HYND, Patrizia TISSELLI, David Edward CLARK, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, Stephen Colin PRICE, John Gary MONTANA
  • NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20160229851
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 11, 2016
    Inventors: George HYND, Patrizia TISSELLI, David Edward CLARK, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Fabien Jean Ghislain ROUSSEL, Stephen Colin PRICE, John Gary MONTANA
  • 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20160075699
    Abstract: The present invention relates to compounds of formula (I) which are inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 17, 2016
    Applicant: Janssen Pharmaceutica N.V.
    Inventors: George HYND, Stephen PRICE, Janusz KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, Patrizia TISSELLI, John Gary MONTANA